Fragile X syndrome carrier screening in pregnant women in Chinese Han population. 2019

Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
Sofiva Genomics Co., Ltd., Taipei, Taiwan.

Fragile X syndrome (FXS) is the most frequent genetic cause of intellectual disability (ID). It was previously believed that the FXS prevalence was low in Chinese population, and the cost-efficiency of FXS carrier screening was questioned. This retrospective observational study was conducted between September 2014 and May 2017 to determine the prevalence of FXS carriers in a large Chinese cohort of pregnant women. The FMR1 CGG repeat status was determined in 20,188 pregnant Taiwanese women and we identified 26 women with premutation (PM). The PM allele was transmitted to the fetus in 17 pregnancies (56.6%), and six of 17 expanded to full mutation (FM). One asymptomatic woman had a FM allele with 280 CGG repeats. Prenatal genetic diagnosis of her first fetus revealed a male carrying a FMR1 gene deletion of 5' UTR and exon 1. Her second fetus was a female carrying a FM allele as well. This is so far the largest study of the FXS carrier screening in Chinese women. The prevalence of premutation allele for FXS in normal asymptomatic Taiwanese women was found to be as high as 0.13% (1 in 777) in this study. The empirical evidence suggests that reproductive FXS carrier screening in Taiwan might be cost-effective.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005006 Ethnicity A group of people with a common cultural heritage that sets them apart from others in a variety of social relationships. Ethnic Groups,Nationality,Ethnic Group,Nationalities
D005260 Female Females
D005600 Fragile X Syndrome A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226) FRAXA Syndrome,FRAXE Syndrome,Martin-Bell Syndrome,Fra(X) Syndrome,Fragile X Mental Retardation Syndrome,Fragile X-F Mental Retardation Syndrome,Mar (X) Syndrome,Marker X Syndrome,Mental Retardation, X-Linked, Associated With Fragile Site Fraxe,Mental Retardation, X-Linked, Associated With Marxq28,X-Linked Mental Retardation and Macroorchidism,FRAXA Syndromes,FRAXE Syndromes,Fragile X Syndromes,Marker X Syndromes,Martin Bell Syndrome,Syndrome, FRAXA,Syndrome, FRAXE,Syndrome, Fragile X,Syndrome, Marker X,Syndrome, Martin-Bell,Syndromes, FRAXA,Syndromes, FRAXE,Syndromes, Fragile X,Syndromes, Marker X,X Linked Mental Retardation and Macroorchidism
D006580 Genetic Carrier Screening Identification of individuals who are heterozygous at a GENETIC LOCUS for a recessive PHENOTYPE. Carriers, Genetic, Detection,Genetic Carriers, Detection,Heterozygote Detection,Carrier Detection, Genetic,Detection, Genetic Carrier,Genetic Carrier Detection,Heterozygote Screening,Carrier Screening, Genetic,Detection, Heterozygote,Screening, Genetic Carrier,Screening, Heterozygote,Screenings, Genetic Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
September 2018, Genetics in medicine : official journal of the American College of Medical Genetics,
Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
March 2012, Genetics in medicine : official journal of the American College of Medical Genetics,
Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
September 2013, BMJ open,
Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
December 2017, Genetics in medicine : official journal of the American College of Medical Genetics,
Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
December 2009, American journal of medical genetics. Part A,
Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
December 1996, Clinical obstetrics and gynecology,
Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
April 2003, Journal of the Chinese Medical Association : JCMA,
Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
March 1993, Lancet (London, England),
Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
March 1993, Lancet (London, England),
Chia-Cheng Hung, and Chien-Nan Lee, and Yu-Chu Wang, and Chih-Ling Chen, and Tze-Kang Lin, and Yi-Ning Su, and Ming-Wei Lin, and Jessica Kang, and Yi-Yun Tai, and Wen-Wei Hsu, and Shin-Yu Lin
March 1993, Lancet (London, England),
Copied contents to your clipboard!